Ionis reports second quarter 2020 financial results and recent business achievements
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Ionis Pharmaceuticals (IONS) Tops Q2 EPS by 4c
August 5, 2020 7:15 AM EDTIonis Pharmaceuticals (NASDAQ: IONS) reported Q2 EPS of ($0.23), $0.04 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $146 million versus the consensus estimate of $148.87 million.
Second Quarter 2020 Financial Results and Highlights
On track to achieve financial guidance of being meaningfully profitable this yearNet income of $8 million on a non-GAAP basis and a net loss of $32 million on a GAAP basisAchieved quarter over quarter growth in commercial and R&D revenuesCommercial revenue from SPINRAZA® (nusinersen) royalties increased to $72... More